Burning rock collaborates with impact therapeutics to provide testing services in developing imp9064 in both us and china

Guangzhou, china, nov. 04, 2021 (globe newswire) -- burning rock biotech limited (nasdaq: bnr, the “company” or “burning rock”) today announced a collaboration with impact therapeutics where burning rock provides testing services in connection with impact therapeutics' development of its atr inhibitor imp9064, which has received the investigational new drug (ind) clearance from the u.s. food and drug administration (fda) for the phase i/ii clinical study, and will begin soon in the u.s. the collaboration will be supported by burning rock's clinical laboratory improvement amendments (clia) certified and college of american pathologists (cap) accredited labs in guangzhou, china and california, u.s.
BNR Ratings Summary
BNR Quant Ranking